Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: Interventional studies

Annals of the New York Academy of Sciences

Volumn 1043, Issue , 2005, Pages 759-766

  Jandeleit Dahm, Karin A ^a   Lassila, Markus ^a   Allen, Terri J ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Advanced glycation end products (AGEs); Aminoguanidine; Atherosclerosis; Cross link breaker; Diabetes; Nephropathy; Pyridoxamine; RAGE; Soluble RAGE

Indexed keywords

4,5 DIMETHYL 3 (2 OXO 2 PHENYLETHYL)THIAZOLIUM; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; ALT 946; AMINOGUANIDINE; ANTIOXIDANT; APOLIPOPROTEIN E; CONNECTIVE TISSUE GROWTH FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; PYRIDORIN; PYRIDOXAMINE; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFICACY; HUMAN; NONHUMAN; PROTEIN CROSS LINKING; PROTEIN GLYCOSYLATION; PROTEIN PROTEIN INTERACTION; RENAL PROTECTION;

EID: 23744435198     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1333.088     Document Type: Conference Paper

References (26)

1. CANDIDO, R., J.M. FORBES, M.C. THOMAS, et al. 2003. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ. Res. 92(7): 785-792.
2. CANDIDO, R., T.J. ALLEN, M. LASSILA, et al. 2004. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 109(12): 1536-1542.
3. LASSILA, M., T.J. ALLEN, Z. CAO, et al. 2004. Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24(5): 935-942.
4. FORBES, J.M., L.T. YEE, V. THALLAS, et al. 2004. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53(7): 1813-1823.
5. PARK, L., K.G. RAMAN, K.J. LEE, et al. 1998. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4(9): 1025-1031.
6. LASSILA, M., K.A. JANDELEIT-DAHM, K.K. SEAH, et al. 2005. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J. Am Soc. Nephrol. 16(2): 363-373.
7. ALLEN, T.J., D. BRASACCHIO, A.C. CALKIN, et al. 2004. Late intervention with pyridoxamine retards progression of atherosclerosis in diabetic apoE knockout mouse (Abstr.). Diabetologia 47(Suppl. 1): A434, no. 1216.
8. SOULIS, T., M.E. COOPER, D. VRANES, et al. 1996. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int. 50(2): 627-634.
9. SOULIS-LIPAROTA, T., M. COOPER, D. PAPAZOGLOU, et al. 1991. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40(10): 1328-1334.
10. ABDEL-RAHMAN, E. & W.K. BOLTON. 2002. Pimagedine: a novel therapy for diabetic nephropathy. Expert Opin. Investig. Drugs 11(4): 565-574.
11. FORBES, J.M., V. THALLAS, M.C. THOMAS, et al. 2003. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. 17(12): 1762-1764.
12. VASAN, S., X. ZHANG, A. KAPURNIOTU, et al. 1996. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382(6588): 275-278.
13. COOPER, M.E., V. THALLAS, J. FORBES, et al. 2000. The cross-link breaker N-phenacylthiazolium bromide prevents vascular advanced glycation end product accumulation. Diabetologia 43(5): 660-664.
14. LASSILA, M., K.K. SEAH, T.J. ALLEN, et al. 2004. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J. Am. Soc. Nephrol. 15(8): 2125-2138.
15. KASS, D.A., E.P. SHAPIRO, M. KAWAGUCHI, et al. 2001. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104(13): 1464-1470.
16. ALDERSON, N.L., M.E. CHACHICH, N.N. YOUSSEF, et al. 2003. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int. 63(6): 2123-2133.
17. BUCCIARELLI, L.G., T. WENDT, W. QU, et al. 2002. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106(22): 2827-2835.
18. WENDT, T.M., N. TANJI, J. QUO, et al. 2003. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 162(4): 1123-1137.
19. WEN, M., S. SEGERER, M. DANTAS, et al. 2002. Renal injury in apolipoprotein E-deficient mice. Lab. Invest. 82(8): 999-1006.
20. KISLINGER, T., N. TANJI, T. WENDT, et al. 2001. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 21(6): 905-910.
21. SAKAGUCHI, T., S.F. YAN, S.D. YAN, et al. 2003. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J. Clin. Invest. 111(7): 959-972.
22. ZHOU, Z., K. WANG, M.S. PENN, et al. 2003. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 107(17): 2238-2243.
23. FORBES, J.M., T. SOULIS, V. THALLAS, et al. 2001. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44(1): 108-114.
24. WILKINSON-BERKA JL, KELLY DJ, KOERNER SM, et al. 2002. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes 51(11): 3283-3289.
25. DEGENHARDT, T.P., N.L. ALDERSON, D.D. ARRINGTON, et al. 2002. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 61(3): 939-950.
26. FORBES, J.M., M.E. COOPER, M.D. OLDFIELD & M.C. THOMAS. 2003. Role of advanced glycation end products in diabetic nephropathy. J. Am. Soc. Nephrol. 14(8 Suppl 3): S254-S258.